Stock IRWD IRONWOOD PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Ironwood Pharmaceuticals, Inc.

Equities

IRWD

US46333X1081

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
7.82 USD -3.22% Intraday chart for Ironwood Pharmaceuticals, Inc. -1.26% -31.64%
Mar. 28 Ironwood Pharmaceuticals, Inc. Announces Positive Results from its Phase II Exploratory STARGAZE Trial of Apraglutide in Patients with Steroid-Refractory Gastrointestinal Acute Graft-versus-Host Disease (SR GI aGVHD) CI
Feb. 29 Wall Street Set to Open Higher Thursday as Inflation Data Meets Forecasts MT

Evolution of the average Target Price on Ironwood Pharmaceuticals, Inc.

Price target over the last 5 years

History of analyst recommendation changes

e795f892a135068faf.0SWtJ6g8ydAymVEjJOKCZXy1QdLqWJLfJRs9_wOqPxw.m1LuYt5lr5lYqGBFT4vqVCzSKuGcGc2ORnhvzU-YXH_pYv5X0HGF50rLNg~be37049fa420637926cfa5f5b1f2ca19

Analyst Recommendations on Ironwood Pharmaceuticals, Inc.

Piper Sandler Adjusts Price Target on Ironwood Pharmaceuticals to $21 From $20, Maintains Overweight Rating MT
Craig-Hallum Starts Coverage on Ironwood Pharmaceuticals with Buy Rating, $21 Price Target MT
JMP Securities Starts Ironwood Pharmaceuticals at Market Outperform, $22 Price Target MT
Piper Sandler Adjusts Price Target on Ironwood Pharmaceuticals to $19 From $16, Maintains Overweight Rating MT
Capital One Securities Initiates IRWD at Overweight with $15 Price Target MT
Wells Fargo Adjusts Ironwood Pharmaceuticals' Price Target to $13 from $12, Maintains Equalweight Rating MT
Piper Sandler Starts Ironwood Pharmaceuticals at Overweight With $16 Price Target MT
IRONWOOD PHARMACEUTICALS : Morgan Stanley Adjusts Price Target on Ironwood Pharmaceuticals to $14 From $13, Maintains Equal-Weight Rating MT
IRONWOOD PHARMACEUTICALS : Morgan Stanley Adjusts Price Target on Ironwood Pharmaceuticals to $12 From $11, Maintains Equal-Weight Rating MT
IRONWOOD PHARMACEUTICALS : Morgan Stanley Adjusts Ironwood Pharmaceuticals' Price Target to $12 from $11, Keeps Equalweight Rating MT
IRONWOOD PHARMACEUTICALS : Credit Suisse Adjusts Ironwood Pharmaceuticals' Price Target to $12 From $11, Maintains Neutral Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
7.82 USD
Average target price
17.4 USD
Spread / Average Target
+122.51%
High Price Target
23 USD
Spread / Highest target
+194.12%
Low Price Target
14 USD
Spread / Lowest Target
+79.03%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Ironwood Pharmaceuticals, Inc.

Piper Sandler
Craig-Hallum
JMP Securities
Capital One Securities
Wells Fargo Securities
Morgan Stanley

Ratings for Ironwood Pharmaceuticals, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. IRWD Stock
  4. Consensus Ironwood Pharmaceuticals, Inc.